MAPT and tauopathy: Intriguingly, despite all three intrabodies displaying the ability to reduce tau in HEK293t cells and primary neuronal cultures, the chimeric intrabody fused to ubiquitin harboring a mutation prone for lysosome-mediated degradation failed to prevent tauopathy in aged P301S mice after the onset of disease.